Latest Breaking News On - Worst itch numeric rating scale - Page 1 : comparemela.com

Arcutis Biotherapeutics, Inc (NASDAQ:ARQT) Q1 2024 Earnings Call Transcript

Arcutis Biotherapeutics, Inc (NASDAQ:ARQT) Q1 2024 Earnings Call Transcript
insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesLatha vairavanSerge belangerDavid topperSeamus fernandezFrank watanabeJohn smitherVikram purohitPatrick burnettArcutis biotherapeuticEmma guttmanTyler van burenPatrick burnetTodd edwardsArcutis biotherapeutics inc

Roflumilast improves atopic dermatitis symptoms in children aged 2 to 5 years

Roflumilast improves atopic dermatitis symptoms in children aged 2 to 5 years
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoByregina schafferLawrence eichenfieldPatrick burnettKristen dowdAmerican academy of dermatology annual meetingUc san diego school of medicineAmerican academyDermatology annualRady childrens hospital san diegoDiego schoolWorst itch numeric rating scaleInvestigator global assessment atopic dermatitis

Late-Breaking Abstracts Highlight Promising Therapies in AD, Hidradenitis Suppurativa

Experts at the American Academy of Dermatology Annual Meeting shared results of research into various topical and systemic therapies for atopic dermatitis (AD) and hidradenitis suppurativa during a late-breaking abstract session.

United statesSan diegoBrian kirbyJonathani silverbergLawrencef eichenfieldJills waibelEli lillyMartinaj porterHealth sciencesAmerican academy of dermatologyBeth israel deaconess medical centerGeorge washington university school of medicineAmerican academy of dermatology annual meetingAmerican journalManaged careAmerican academy

Elafibranor Appears Effective, Safe for PBC

Treatment with elafibranor showed significantly greater improvements in relevant biochemical indicators of cholestasis than the placebo.

United statesKris kowdleyLiver institute northwest in seattleLiver institute northwestNew england journalWorst itch numeric rating scaleBiliary diseaseAllbladder diseaseIpid managementLiver fibrosisLiver diseaseHepatic impairmentTransplantation of the liverEpatic transplantationLiver transplantationCv risk

Zoryve Topical Foam Approved for Seborrheic Dermatitis

The FDA has approved Zoryve® (roflumilast) topical foam, 0.3% for the treatment of seborrheic dermatitis in patients 9 years of age and older.

United statesArcutis biotherapeuticsAndrew blauveltDrug administrationOregon medical research centerZoryve direct programInvestigator global assessmentWorst itch numeric rating scale